Results 191 to 200 of about 8,564,356 (290)

Ultrafast visual detection of Streptococcus suis via HtpsC‐targeted LAMP–CRISPR–Cas12a coupled with lateral flow immunochromatography

FEBS Open Bio, EarlyView.
A rapid visual test combines DNA amplification, CRISPR–based target verification, and a lateral flow strip to detect Streptococcus suis. The assay gives results in about 45 min, reduces false‐positive interpretation, and does not require fluorescence equipment.
Liu‐xin Li, Miao Xin, Xiao‐wen Cui, Shi‐yin Yu, Fei Meng, Min Cao, Xiao‐hui Xiong, Yi‐chen Lu   +7 more
wiley   +1 more source

Association of donor-specific antibodies with adverse outcomes in solid organ transplantation: A systematic review and meta-analysis of 69 studies. [PDF]

Front Immunol
Kang ZY, Han XY, Liu C, Liu W, Li DH.
europepmc   +1 more source

Fluorination: A strategy to tune the interactions of molecules and nanoscale systems with biological matter

FEBS Open Bio, EarlyView.
This minireview explores fluorination as a key strategy to optimize therapeutic molecules and nanocarriers. By incorporating different fluorinated motifs—from single atoms to linear and branched chains—drug delivery, cellular uptake, and colloidal stability can be improved and fine‐tuned.
Martina Beccalli, Beatrice Lucia Bona, Francesca Baldelli Bombelli   +2 more
wiley   +1 more source

Donor-specific antibodies against HLA-C, HLA-DP and HLA-DQ and their implications in kidney transplantation. [PDF]

World J Transplant
Khalil MAM, Sadagah NM, Hediki I, Tan J, Al-Qurashi SH.   +4 more
europepmc   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

FEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao, Leonie Meyer, Madita Braun, Katharina Otte, Celine Bitter, Maite Pawlik, Hartmann Raifer, Frederik Helmprobst, Axel Pagenstecher, Hans Urban, Michael C. Burger, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jarmila Jedelská, Shamim Bagheri, Behrooz H. Yousefi, Pietro Di Fazio, Markus Luster, Andreas H. Mahnken, Andreas Neubauer, Andreas Burchert, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +23 more
wiley   +1 more source

Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation

BACKGROUND: De novo donor-specific HLA antibodies (DSA) are a risk for poor graft outcomes, but there is little evidence of their long-term effect in pediatric cardiac transplantation or of the effect of transient versus persistent DSA found using newer ...
Hasan A, Carter V, Gennery AR, Irving CA, Parry G, Griselli M, Kirk CR   +6 more
core  

Impact of low-level pretransplant donor-specific antibodies detected by the Luminex platform on acute rejection and long-term graft survival. [PDF]

World J Transplant
Abbas K, Mubarak M, Musharraf W, Hafeez AR, Aziz T, Zafar MN.   +5 more
europepmc   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction. [PDF]

Circ Heart Fail
Goldberg JF, Tian X, Bon A, Xu Y, Gerhard E, Brower R, Jang MK, Kong H, Andargie TE, Park W, Najjar SS, Tchoukina I, Shah KB, Hsu S, Rodrigo ME, Marboe C, Berry GJ, Valantine HA, Shah P, Agbor-Enoh S.   +19 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source